Press Release | ERDERA Clinical Trial Call

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

ERDERA trainings template (14)

Diagnostic Research Workstream Webinar Series – Session 3: The Data Reanalysis Approach

November 25 @ 1:00 pm - 2:00 pm
Intended for clinicians, clinical geneticists, researchers, data analysts and ERN members working in rare diseases
European Union flag ERDERA

Horizon Europe 2027: what the funding programme means for the rare disease research community

Horizon Europe’s 2026–2027 work programme combines broad health research opportunities with changes to applications and new support for taking existing results further.
GAM 2026 Badge

ERDERA General Assembly sets priorities for an integrated and delivery-focused third year

ERDERA’s third General Assembly brought partners together in Coimbra to review its second year, strengthen connections across the partnership and align priorities for a more integrated and delivery-focused third year.
ERDERA 2026 Open Session

From individual cases to new treatment pathways: ERDERA Open Session focuses on ultra-rare diseases

ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.

ERDERA Search